Wall Street brokerages expect that Fennec Pharmaceuticals Inc (NASDAQ:FENC) will report earnings per share of ($0.09) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Fennec Pharmaceuticals’ earnings. Fennec Pharmaceuticals also posted earnings per share of ($0.09) in the same quarter last year. The firm is scheduled to report its next quarterly earnings report on Monday, May 13th.
According to Zacks, analysts expect that Fennec Pharmaceuticals will report full year earnings of ($0.15) per share for the current year. For the next year, analysts expect that the business will report earnings of $1.44 per share. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Fennec Pharmaceuticals.
Fennec Pharmaceuticals (NASDAQ:FENC) last issued its earnings results on Wednesday, March 13th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01).
Several analysts recently weighed in on FENC shares. HC Wainwright set a $18.00 target price on shares of Fennec Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 21st. Wedbush reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Thursday. Finally, Zacks Investment Research cut shares of Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $15.00.
NASDAQ:FENC traded down $0.02 during mid-day trading on Friday, hitting $5.81. The stock had a trading volume of 88,600 shares, compared to its average volume of 43,788. The stock has a market cap of $136.29 million, a price-to-earnings ratio of -12.26 and a beta of -0.23. Fennec Pharmaceuticals has a twelve month low of $5.33 and a twelve month high of $14.99.
A number of large investors have recently modified their holdings of the stock. Rhumbline Advisers acquired a new position in shares of Fennec Pharmaceuticals during the fourth quarter valued at $87,000. Weiss Multi Strategy Advisers LLC bought a new position in shares of Fennec Pharmaceuticals during the fourth quarter worth about $160,000. Geode Capital Management LLC grew its holdings in shares of Fennec Pharmaceuticals by 16.0% during the fourth quarter. Geode Capital Management LLC now owns 39,489 shares of the company’s stock worth $251,000 after buying an additional 5,441 shares in the last quarter. Vanguard Group Inc grew its holdings in shares of Fennec Pharmaceuticals by 7.1% during the third quarter. Vanguard Group Inc now owns 43,488 shares of the company’s stock worth $357,000 after buying an additional 2,868 shares in the last quarter. Finally, United Services Automobile Association grew its holdings in shares of Fennec Pharmaceuticals by 48.6% during the third quarter. United Services Automobile Association now owns 82,268 shares of the company’s stock worth $675,000 after buying an additional 26,920 shares in the last quarter. 48.99% of the stock is currently owned by hedge funds and other institutional investors.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Further Reading: Systematic Risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.